Efficacy and safety of novel anticoagulants compared with established agents.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 3573404)

Published in Ther Adv Hematol on June 01, 2011

Authors

Iwona Rybak1, Michael Ehle, Leo Buckley, John Fanikos

Author Affiliations

1: Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.

Associated clinical trials:

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) | NCT00412984

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) | NCT00781391

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study | NCT00439777

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism | NCT00643201

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). | NCT00986154

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome | NCT00809965

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE (RE-SONATE) | NCT00558259

Secondary Prevention of Venous Thrombo Embolism (VTE). (RE-MEDY) | NCT00329238

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism | NCT00633893

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (RE-COVER II) | NCT00680186

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN) | NCT00571649

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness (ADOPT) | NCT00457002

Articles by these authors

The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11

International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med (2004) 1.55

Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med (2011) 1.48

Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol (2005) 1.34

Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol (2011) 1.19

How many hospital pharmacy medication dispensing errors go undetected? Jt Comm J Qual Patient Saf (2006) 1.06

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum (2005) 1.06

Time trends in warfarin-associated hemorrhage. Am J Cardiol (2004) 1.02

Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01

Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis (2007) 0.99

Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98

Anticoagulation-associated adverse drug events. Am J Med (2011) 0.96

Evaluation of dexmedetomidine versus propofol-based sedation therapy in mechanically ventilated cardiac surgery patients at a tertiary academic medical center. Crit Pathw Cardiol (2010) 0.95

Technology utilization to prevent medication errors. Curr Drug Saf (2010) 0.95

Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95

Patient education program for venous thromboembolism prevention in hospitalized patients. Am J Med (2012) 0.94

Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93

Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90

Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 0.87

Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy (2011) 0.85

Cardiology patient pages. Prevention of deep vein thrombosis and pulmonary embolism. Circulation (2004) 0.84

The nonpharmacist business manager: key qualifications and skills for success. Am J Health Syst Pharm (2011) 0.83

New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82

New antithrombotics: the impact on global health care. Thromb Res (2011) 0.79

Medication errors in a pharmacy-based bar-code-repackaging center. Am J Health Syst Pharm (2006) 0.79

Venous thromboembolic events in hospitalised medical patients. Thromb Haemost (2009) 0.78

Venous thromboembolism in hospitalized patients with active cancer. Clin Appl Thromb Hemost (2013) 0.77

Prescription of fondaparinux in hospitalised patients. Thromb Haemost (2009) 0.77

Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol (2004) 0.77

Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clin Appl Thromb Hemost (2011) 0.76

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol (2013) 0.75

A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hosp Pharm (2016) 0.75

Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients. Ann Pharmacother (2003) 0.75

Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias. Am J Health Syst Pharm (2009) 0.75

Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation (2012) 0.75

Dronedarone: a review of characteristics and clinical data. Crit Pathw Cardiol (2010) 0.75

Bridging Experience With Eptifibatide After Stent Implantation. Crit Pathw Cardiol (2016) 0.75

Interleukin-1 Blockade for the Treatment of Pericarditis. Eur Heart J Cardiovasc Pharmacother (2017) 0.75

Review of Nonformulary Medication Approvals in an Academic Medical Center. Jt Comm J Qual Patient Saf (2016) 0.75

Consultant's Playbook: A Survey of Pharmacy Consultant Experiences Among Hospitals In the University HealthSystem Consortium. P T (2013) 0.75

Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia. Pharmacotherapy (2013) 0.75

Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost (2008) 0.75